Shield Therapeutics Share Discussion Threads

[frrinvest] 04/3/2021 21:48

Good purchase by lady NED

[amaretto1] 04/3/2021 19:25

End of the day ... it's still a 75 k vote of confidence !

[whatno] 04/3/2021 19:18

I wonder what other shares she buys :-)

[whatno] 04/3/2021 19:17

hmm.. the director's wife bought 200,000 at 37p

[amaretto1] 04/3/2021 18:36

RNS .... large share purchase ! They know the huge opportunity here

[powerp2] 04/3/2021 15:44

He doesn't seem to hang around places more recently

[galaxy enforcer] 04/3/2021 15:26

Our Mr Groch certainly has an interesting CV with links to some of the big boys such as Novartis and Merck

hxxps://www.linkedin.com/in/brian-groch-6487503

[machinist] 04/3/2021 15:19

Got my 2 for 17 share offer today from Halifax, a few more lead weights around my ankles are not going to to make much difference ....glug gasp glug

[galaxy enforcer] 04/3/2021 14:53

So taking all things into consideration we are looking at 8p possible downside versus 150p+ possible upside. Risk vs Reward certainly in the right direction.

If our new Sales Director for the US delivers the anticipated return and increased profitability will be reflected quickly in the share price.

[daveboy19] 04/3/2021 14:43

RNS dated 22/4/20 - reads even worse now this joint collaboration!

Shield Therapeutics plc

("Shield" or the "Group" or the "Company")



Directorate Change



Tim Watts to succeed Carl Sterritt as CEO

Carl Sterritt to actively support ongoing US partnering activities



London, UK, 22 April 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), a novel oral iron treatment, announces that, following discussions with major shareholders and with mutual agreement, Carl Sterritt has informed the Company of his decision to resign from the Board and his role as Chief Executive Officer with immediate effect. Tim Watts has been appointed as Chief Executive Officer from his role as Chief Financial Officer (CFO), which he has occupied since August 2018 and will be appointed to the Board in due course. Tim has extensive biotech and Pharmaceutical experience, having previously been CFO of Oxford BioMedica PLC and Archimedes Pharma Ltd, preceded by 22 years at AstraZeneca.



Recognising the value to Shield and its shareholders of successfully completing the ongoing US partnering activities for Feraccru®/Accrufer®, Carl has willingly agreed to actively support Tim over the coming months, thereby ensuring his knowledge and expertise of Feraccru®/Accrufer® are readily available to the Company through to the closing of a partnering agreement in the United States.



Carl founded the Company in 2008. Having first identified the unique potential of Feraccru®/Accrufer®, he acquired the product and then had the vision and determination to enable the Company to develop Feraccru®/Accrufer® to where it is today, approved in both Europe and the United States for the treatment of iron deficiency in adults, currently marketed in Europe and seeking a US commercialisation partner, and licensed to a partner that will complete the development programme and then commercialise Feraccru®/Accrufer® in China. He was also responsible for the identification, acquisition and funding of the Company's second asset, PT20, which now requires just one further positive study before marketing authorisations can be requested.



James Karis, Chairman of Shield Therapeutics, said: "On behalf of the Board, I would like to extend our sincere thanks to Carl for the very substantial contribution that he has made to Shield since he founded the Company. His entrepreneurial approach, drive and determination have enabled the Company to successfully develop Feraccru®/Accrufer® and build the business to what it is today. His ongoing support is welcome and I wish him and his family all the best for the future. Looking forward, I am very pleased that Tim Watts has agreed to assume the role of CEO. His knowledge of the Company and his strong biopharmaceutical background will be critical to further advancing the business."



Carl Sterritt added: "Since founding the Company over ten years ago I am immensely proud of what we have achieved at Shield Therapeutics and my sincere thanks go to all of those colleagues who have been part of what has been an incredible journey for me. Feraccru®/Accrufer® is a uniquely effective product that I am sure will go on to become a major commercial success and in the immediate future I look forward to supporting Tim and the team in completing the partnering process for Feraccru®/Accrufer® in the USA."



Tim Watts said: "I am honoured to have the opportunity to take on this role at this important time for Shield and thank the Board for its support. I am also pleased that Carl will serve in an advisory capacity so that we can ensure a smooth transition. Shield has a strong and dedicated team, and I look forward to working together to achieve the Company's goals."

THEY SHOULD HANG THEIR HEADS IN SHAME.

[daveboy19] 04/3/2021 14:37

You forgot to add CEO and co-founder leaves abruptly, whilst RNS states 'Carl staying on to push US deal through' or words to that effect. Lies, all of it. He sold his shares and went to work for another company!

[daveboy19] 04/3/2021 14:22

Yes, sent my question in yesterday for Timothy to answer. Could say it was along those lines.

[powerp2] 04/3/2021 14:18

Toxic emotions?
Shareholder value destroyed
Lied to about U.S. position
Massively diluted when old we wouldn't be
Short changed on low ball placing
Shall I continue?

[t0pgrader] 04/3/2021 13:59

In case anyone doesn't know there's a co presentation coming on InvestorMeetCompany:

SHIELD THERAPEUTICS PLC - Investor Presentation will start at 9th Mar 2021 at 4:00pm GMT.

You can unburden yourself of all your toxic emotions by submitting your questions in advance

[daveboy19] 04/3/2021 12:55

That was a timid BOOOM, Hod - more like a little parp :)

[daveboy19] 04/3/2021 12:51

Wish I was only £20K in the hole ....

[powerp2] 04/3/2021 12:27

I'm £20k in the hole so I really want him to succeed!

[t0pgrader] 04/3/2021 12:02

> power. Groch worked for Acasti (not Avasti) and their lead product was CaPre (not CAPA) a derivative from krill-oil

[hodhasharon] 04/3/2021 11:59

200p first target....here we go.

Monday RNS anyone?

[daveboy19] 04/3/2021 11:56

powerp2 - We do know that there are 15,000 physicians surveyed in the US who have stated that Accrufer would be the first product of choice to give to their patients when/if available. The doubt was STX under Watts achieving the route. I believe this guy will give us the access, and the rest will follow.
A top, respected Chinese pharma would not cough up $13.4M for a dud !! (just for starters).

[hodhasharon] 04/3/2021 11:18

Here comes the BOOOM!!!!

[powerp2] 04/3/2021 11:13

Damn predictive text
Now find = norgine

[powerp2] 04/3/2021 11:04

I look forward to hearing from Mr Groch. TW has no credibility who me not only misleading us answering questions at the last few presentations (tbf probably means he doesn't call the shots - that begs the question of his big salary).
Mr Groch comes from Avasti pharmaceutical which had a similar challenge with a product called CaPa. They raised money and Groch headed a sales team that said it would sell like hot cakes. For whatever reason it didn't, the entire sales team released and the company i believe is " considering its options"
The crumb of comfort is that he's been in the business all his life and will understand the route to market etc. Also he isn't TW!
My big fear is the product is a dud. Not that it doesn't work but it can't capture sufficient volume at an acceptable price to e vile - I have to assume Now find aren't fools and they seem to have as little impact with it.
For me the saddest thing is that STX and how it's carried on is crushing my natural optimism.
🙏

[onceaday] 04/3/2021 08:05

The US guy seems to have been in sales & marketting roles and chief operating officer roles for a good amount of time based on his linkedIn profile. I thing it worth digging a bit deeper into his track record but on the face of it he seems well qualified. If he comes across well in a few investor presentations sentiment will change and FOMO will kick in. He's American and has been in sales for most of his career so he will certainly outshine Tim Watts when selling the Shield story. He may even generate some good press in the US. If he stirs even a small amount of interest from US retail investors the price will bid up.

I agree with many of the.points made questioning the viability of the business given the weak European sales but the share price of small loss making AIM stocks often has little to do with fundamentals!